open access

Vol 66, No 5 (2016)
Short reviews
Published online: 2017-03-29
Get Citation

Tamoxifen — no longer a golden standard for adjuvant therapy in the treatment of premenopausal patients with hormone-sensitive breast cancer

Renata Duchnowska
DOI: 10.5603/NJO.2016.0073
·
Nowotwory. Journal of Oncology 2016;66(5):415-417.

open access

Vol 66, No 5 (2016)
Short reviews
Published online: 2017-03-29

Abstract

For several decades, in breast cancer patients with a luminal subtype, tamoxifen has been the main endocrine therapy in adjuvant setting in both pre- and postmenopausal women. However, it may be suboptimal in some premenopausal patients. The results of prospective, randomised studies SOFT/TEXT clearly demonstrated that the combination of OFS with TAM or IA is more effective than monotherapy TAM in breast cancer premenopausal women with hormone-sensitive early breast cancer and a high risk of recurrence.

Abstract

For several decades, in breast cancer patients with a luminal subtype, tamoxifen has been the main endocrine therapy in adjuvant setting in both pre- and postmenopausal women. However, it may be suboptimal in some premenopausal patients. The results of prospective, randomised studies SOFT/TEXT clearly demonstrated that the combination of OFS with TAM or IA is more effective than monotherapy TAM in breast cancer premenopausal women with hormone-sensitive early breast cancer and a high risk of recurrence.

Get Citation

Keywords

tamoxifen, aromatase inhibitor, ovarian function suppression, breast cancer, premenopausal women

About this article
Title

Tamoxifen — no longer a golden standard for adjuvant therapy in the treatment of premenopausal patients with hormone-sensitive breast cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 5 (2016)

Pages

415-417

Published online

2017-03-29

DOI

10.5603/NJO.2016.0073

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(5):415-417.

Keywords

tamoxifen
aromatase inhibitor
ovarian function suppression
breast cancer
premenopausal women

Authors

Renata Duchnowska

References (29)
  1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747–752.
  2. Goldhirsch A, Winer EP, Coates AS, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9): 2206–2223.
  3. Creighton C, Fu X, Hennessy B, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Research. 2010; 12(3): R40.
  4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61–70.
  5. Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10): 573–583.
  6. Coates AS, Winer EP, Goldhirsch A, et al. Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8): 1533–1546.
  7. Cardoso F, Costa A, Norton L, et al. European School of Oncology, European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014; 25(10): 1871–1888.
  8. Jassem J, Krzakowski M. Rak piersi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Via Medica, Gdańsk 2013: 211–265.
  9. www.nccn.org.
  10. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000; 355(9218): 1869–1874.
  11. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17(8): 2365–2370.
  12. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001(30): 44–51.
  13. Francis P, Regan M, Fleming G, et al. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine. 2015; 372(5): 436–446.
  14. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014; 32(35): 3948–3958.
  15. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013; 381(9869): 805–816.
  16. Gray R, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology. 2013; 31(18_suppl): 5–5.
  17. Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS One. 2014; 9(2): e88238.
  18. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011; 89(5): 718–725.
  19. Jager NGL, Rosing H, Schellens JHM, et al. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat. 2014; 143(3): 477–483.
  20. Hennig EE, Piatkowska M, Karczmarski J, et al. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer. 2015; 15: 570.
  21. Pagani O, Regan MM, Walley BA, et al. TEXT and SOFT Investigators, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2): 107–118.
  22. Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015; 16(7): 848–858.
  23. Ribi K, Luo W, Bernhard J, et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016; 34(14): 1601–1610.
  24. Bellet M, Gray KP, Francis PA, et al. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016; 34(14): 1584–1593.
  25. Gnant M, Mlineritsch B, Schippinger W, et al. ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7): 679–691.
  26. Gnant M, Mlineritsch B, Stoeger H, et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2): 313–320.
  27. Dowsett M, Forbes JF, Bradley R, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341–1352.
  28. Senkus E, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v8–30.
  29. Jassem J, Krzakowski M. Rak piersi: Praktyczny przewodnik dla lekarzy. Wyd. 2. Via Medica, Gdańsk 2014.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl